Welichem Biotech Inc.

Welichem Biotech Inc.

April 26, 2007 19:01 ET

Welichem Filed Quarterly Report for Period Ended February 28, 2007

BURNABY, BRITISH COLUMBIA--(CCNMatthews - April 26, 2007) - Welichem Biotech Inc. (the "Company") (TSX VENTURE:WBI) announced today that the Company filed its third quarter financials and MD & A. The net loss for the 3-month period ended February 28, 2007 was $812,781 (2006- $306,241) and 1 cent per share (2006 - 1 cent per share). The net loss for the 9-month period ended February 28, 2007 was $2,511,360 (2006 - $1,623,947) and 4 cents per share (2006 - 6 cents per share).

Detailed information is available on SEDAR website (www.sedar.com).

About Welichem Biotech Inc.

Welichem Biotech Inc. is a publicly-traded biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer.


York Yingping Guo, President & Chief Executive Officer

This press release contains forward-looking statements that include our belief as to the potential of our products. Certain risks and uncertainties such as our ability to successfully commercialize the products could cause the Company's actual results to differ materially from those in the forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Contact Information